Robert Myles Elfont Net Worth

What's Robert Elfont's mailing address?

Robert's mailing address filed with the SEC is C/O AIMMUNE THERAPEUTICS, INC., 8000 MARINA BOULEVARD, SUITE 300, BRISBANE, CA, 94005-1884.

Insiders trading at Aimmune Therapeutics Inc

Over the last 9 years, insiders at Aimmune Therapeutics Inc have traded over $19,285,948 worth of Aimmune Therapeutics Inc stock and bought 61,698,079 units worth $2,225,231,200 . The most active insiders traders include Des Produits Nestle S.A. So..., Patrick G Enright et Des Produits Nestle S.A.Nes.... On average, Aimmune Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $21,038,606. The most recent stock trade was executed by Des Produits Nestle S.A. So... on 13 October 2020, trading 54,117,287 units of AIMT stock currently worth $1,867,046,402.

What does Aimmune Therapeutics Inc do?

Aimmune Therapeutics Inc executives and stock owners

Aimmune Therapeutics Inc executives and other stock owners filed with the SEC include:

• Stacey Denenberg Seltzer,
  Director
• Jeffrey H Knapp,
  Chief Operating Officer
• Susan E. Barrowcliffe,
  General Manager, Europe
• Capital Partners Ii, Llc Ta...,
  
• Kathryn E Falberg,
  Director
• Daniel C Md Adelman,
  Chief Medical Officer
• Mary M. Rozenman,
  See Remarks
• Capital Management Ii, Llc ...,
  
• Capital Partners Ii, Llc Lo...,
  
• Gregory Behar,
  Director
• Douglas T. Sheehy,
  See Remarks
• Mark T Iwicki,
  Director
• Eric Bjerkholt,
  Chief Financial Officer
• Mark Mcdade,
  Director
• Warren L. De Souza,
  Chief Financial Officer
• Robert Myles Elfont,
  Chief Medical Officer
• Jayson Donald Alexander Dallas,
  President and CEO
• Health Science Us Holdings,...,
  
• Des Produits Nestle S.A.Nes...,
  
• Bakker Juliet Tammenoms,
  10% owner
• Stephen George Dilly,
  See Remarks
• Andrew Oxtoby,
  Chief Commercial Officer
• Capital Partners Ii, Llc Ta...,
  
• Patrick G Enright,
  Director
• Brett K Haumann,
  Director
• Des Produits Nestle S.A. So...,
  10% owner